Clinical Trials Sponsored by Danube Pharmaceuticals, Inc.

Total 5010 results

Mitsubishi Tanabe Pharma America Inc.

Completed

Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

Vasomotor Symptoms (VMS)

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

EPP | XLP

Spain, United States, Germany, Norway, Italy, Australia, Canada, Japan, Sweden, United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Mass Balance Study With MT-8554 (MT-8554 MB)

Healthy Volunteer

United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
Mylan Pharmaceuticals Inc
Momenta Pharmaceuticals, Inc.

Completed

Extension Study of MYL-1701P-3001 for Safety and Efficacy

Diabetic Macular Edema

India
Massachusetts General Hospital
Alkermes, Inc.; Otsuka America Pharmaceutical; Eisai Inc.; Janssen Pharmaceuticals and other collaborators

Recruiting

National Pregnancy Registry for Atypical Antipsychotics

Depression | Schizophrenia | Schizoaffective Disorder | Bipolar Disorder | Use of Atypical Antipsychotics During Pregnancy

United States
Mitsubishi Tanabe Pharma America Inc.

Recruiting

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP (INSPIRE)

Erythropoietic Protoporphyria (EPP) | X-Linked Protoporphyria (XLP)

United States, Spain, France, United Kingdom, Japan, Italy, Australia, Bulgaria, Czechia, Netherlands, Poland
Mitsubishi Tanabe Pharma America Inc.

Recruiting

Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

Spinal Cord Injury

United States, Canada, Japan
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Erythropoietic Protoporphyria (EPP)

United States
Mitsubishi Tanabe Pharma America Inc.

Terminated

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

ALS

United States, Korea, Republic of, Canada, Germany, Japan, Italy, Switzerland
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety and Efficacy Study of MT-2990 in Women With Endometriosis

Endometrial Related Pain

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects

Healthy Subjects

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety Study of Oral Edaravone Administered in Subjects With ALS

ALS

United States, Canada, Japan, France, Germany, Italy
Mitsubishi Tanabe Pharma America Inc.

Completed

Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor (MT-7117 BA DDI)

Healthy Volunteer

Germany
Mitsubishi Tanabe Pharma America Inc.

Completed

Definitive QT Study With MT-8554 (MT-8554 DQT)

Healthy Volunteer

United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Healthy Subjects

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Renal Impairment | Normal Renal Function

Germany
Mylan Pharmaceuticals Inc
Momenta Pharmaceuticals, Inc.

Completed

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME) (DME)

Diabetic Macular Edema

Japan, United States, Czechia, Germany, Hungary, India, Latvia, Poland, Russian Federation
Novartis Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation

Completed

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Spain, United States, Belgium, Germany, Italy, Israel, Australia, France, United Kingdom, Netherlands, Czechia, Japan, Canada, Greece, Poland
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

Chronic Hepatitis C

Japan
Novartis Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Renal Transplantation
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

Hepatitis C

Japan
NovaBay Pharmaceuticals, Inc.
Novum Pharmaceutical Research Services; International Dermatology Research,...

Completed

Safety and Efficacy of Topical NVC-422 Gel in Impetigo

Impetigo

Dominican Republic
Nucorion Pharmaceuticals, Inc.
Medpace, Inc.; Ligand Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects

Hepatitis B

United States
Corbus Pharmaceuticals Inc.
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Solid Tumor, Adult

United States, Spain, Turkey, United Kingdom
MingSight Pharmaceuticals, Inc
Shenzhen MingSight Relin Pharmaceutical Co., Ltd

Recruiting

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)

China
ChemGenex Pharmaceuticals

Terminated

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

Myeloid Leukemia, Chronic, Chronic-Phase | Myeloid Leukemia, Chronic | Myeloid Leukemia, Chronic, Accelerated-Phase | Blast Phase

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Follicular Lymphoma

Italy, Israel, Germany, France, Greece, Spain, Switzerland
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

France, United States, Spain, Korea, Republic of, Australia, Israel, India, Thailand, China, Czech Republic, Belgium, New Zealand, Russian Federation, Finland, South Africa, United Kingdom, Italy, Brazil, Hungary, Puerto Rico, A... and more
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

Amyloidosis

United States
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Bacterial Infections and Mycoses | Cholecystitis | Appendicitis | Peritonitis | Pancreatitis
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Bacterial Infections and Mycoses | Cholecystitis | Appendicitis | Peritonitis | Pancreatitis
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Hospital-Acquired Pneumonia

Pneumonia
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Urinary Tract Infections | Pyelonephritis
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

Tumors | Non-Hodgkins's Lymphoma

United States
Janssen Pharmaceutical K.K.
Mitsubishi Tanabe Pharma Corporation

Completed

A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Japan
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Belgium
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Austria
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

Multiple Myeloma

Belgium, France, Germany
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Urinary Tract Infections | Pyelonephritis
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Non-Small Cell Lung Cancer

Belgium
ChemGenex Pharmaceuticals

Completed

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Hematologic Tumors

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

Multiple Myeloma | Non-Hodgkin's Lymphoma

Israel, Italy, Poland, South Africa, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Ventilator-Associated Pneumonia

Pneumonia | Ventilators, Mechanical

Clinical Trials Sponsored by Danube Pharmaceuticals, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations